Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 44.66%.

  • Catalyst Pharmaceuticals' EBIT Margin rose 51000.0% to 44.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.76%, marking a year-over-year increase of 69700.0%. This contributed to the annual value of 39.68% for FY2024, which is 178800.0% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported EBIT Margin of 44.66% as of Q3 2025, which was up 51000.0% from 45.24% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBIT Margin ranged from a high of 53.79% in Q2 2022 and a low of 36.21% during Q3 2023
  • Over the past 5 years, Catalyst Pharmaceuticals' median EBIT Margin value was 43.55% (recorded in 2021), while the average stood at 37.75%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -800700bps in 2023, then surged by 757700bps in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' EBIT Margin stood at 33.26% in 2021, then surged by 52bps to 50.7% in 2022, then fell by -26bps to 37.71% in 2023, then rose by 18bps to 44.31% in 2024, then rose by 1bps to 44.66% in 2025.
  • Its EBIT Margin stands at 44.66% for Q3 2025, versus 45.24% for Q2 2025 and 44.81% for Q1 2025.